Omeros | OMER - Current Liabilities


Omeros reported $85.5M in Current Liabilities for its fiscal quarter ending in June of 2025.





Current Liabilities Change Date
Adma Biologics USD 95.28M 19.52M Sep/2026
Alnylam Pharmaceuticals USD 2.06B 550.49M Sep/2026
BioMarin Pharmaceutical USD 1.6B 59.17M Sep/2026
Cytokinetics USD 353.42M 171.99M Sep/2026
Gilead Sciences USD 12B 982M Sep/2026
Heron Therapeutics USD 92.14M 1.63M Jun/2026
Immunic USD 38.36M 7.74M Mar/2026
Insmed USD 596.57M 157.83M Sep/2026
Knight Therapeutics CAD 165.26M 12.58M Dec/2025
MacroGenics USD 108.82M 12.88M Jun/2026
Omeros USD 85.5M 2.28M Jun/2025
Pacira USD 126.1M 4.08M Sep/2026
Pfizer USD 31.73B 920M Sep/2026
Rockwell Medical USD 10.95M 259K Jun/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sarepta Therapeutics USD 656.35M 153.44M Sep/2026
United Therapeutics USD 624.3M 16.5M Sep/2026
Vertex Pharmaceuticals USD 5B 1.06B Sep/2026